semaglutide或可改善寻求肥胖治疗的成年人的饮食障碍症状和体型感知
Semaglutide may improve eating disorder symptoms and body image in adults seeking obesity treatment
一项新研究发现,接受semaglutide治疗的肥胖患者在饮食障碍行为和体型感知方面有显著改善,相比安慰剂组有更大程度的体重减轻和心理健康的改善。
研究发现semaglutide在肥胖治疗中可能改善饮食障碍症状和体型感知,为相关治疗提供新视角。
Adults receiving semaglutide for obesity treatment experienced greater improvements in several measures of disordered eating, eating disorder symptoms and body image concerns compared with participants receiving placebo, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania. The study was published in the International Journal of Eating Disorders.
"Given the growing use of GLP-1 medications for obesity treatment, there has been interest in understanding how these therapies affect disordered eating behaviors and body image," said Kelly Costello Allison, director of Penn's Center for Weight and Eating Disorders (CWED) and the study's first author, who presented findings of the study at ObesityWeek 2026 in Washington, D.C.
"Our findings suggest that semaglutide not only supports weight loss but may also improve several measures of eating disorder psychopathology and loss-of-control eating in many patients," said Jena Tronieri, senior research investigator at Penn's CWED and senior author of the study.
Improvements in eating behaviors and body image
The study included 120 adults seeking treatment for obesity. Participants were randomly assigned to receive either semaglutide 2.4 mg or placebo alongside a structured lifestyle intervention that included dietary counseling and physical activity guidance.
Participants receiving semaglutide experienced substantially greater weight loss than those receiving placebo, losing an average of approximately 15% of their body weight after 60 weeks, compared with about 3% in the placebo group.
Over the course of the 60-week study, participants treated with semaglutide experienced significantly greater improvements in several measures of eating-related and psychological health compared with those receiving placebo.
The medication was associated with larger reductions in loss-of-control eating, overall eating disorder psychopathology and concerns related to body weight and shape. Participants in the semaglutide group also reported greater improvements in feelings of body dissatisfaction and body image.
Among individuals who entered the study with binge eating episodes or full or subthreshold binge-eating disorder, those receiving semaglutide were more likely to achieve remission and abstinence from binge eating behaviors. The emergence of new eating disorder symptoms and clinically meaningful worsening of eating-related psychopathology were uncommon in both treatment groups, suggesting that semaglutide treatment was generally associated with improvements, rather than deterioration, in eating-related outcomes.
The researchers noted that while average outcomes were favorable, a small number of participants experienced disordered eating behaviors during the study, underscoring the importance of continued monitoring, particularly among individuals with a history of eating disorders.
The authors noted that larger studies will be needed to further evaluate the relationship between GLP-1 medications and eating disorders, particularly among individuals with diagnosed binge-eating disorder or a history of other eating disorders.
"These results are encouraging, particularly for patients who struggle with both obesity and binge eating," said Allison. "At the same time, our findings highlight the importance of routinely assessing eating behaviors throughout treatment, particularly in patients with an eating disorder history, so that patients who develop concerning symptoms can receive appropriate care."
Publication details
Kelly C. Allison et al., Disordered Eating Attitudes and Behaviors in Individuals With BMI > 27 kg/m 2 Treated by Semaglutide: A 60‐Week Randomized Placebo‐Controlled Trial, International Journal of Eating Disorders (2026). DOI: 10.1002/eat.70253
Journal information: International Journal of Eating Disorders
Key medical concepts
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Semaglutide may improve eating disorder symptoms and body image in adults seeking obesity treatment (2026, November 18) retrieved 18 November 2026 from https://medicalxpress.com/news/2026-11-semaglutide-disorder-symptoms-body-image.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com